Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

NCT06553885 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer
Hepatocellular Carcinoma

Interventions

DRUG: Enfortumab Vedotin

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]